| Trial ID: | L5909 |
| Source ID: | NCT06495931
|
| Associated Drug: |
Hrs-1780 Tablets
|
| Title: |
Study on Drug Interaction of HRS-1780 Tablets, Henagliflozin Tablets, Metformin Tablets and HRS-7535 Tablets in Healthy Human
|
| Acronym: |
|
| Status: |
NOT_YET_RECRUITING
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
Type 2 Diabetes Mellitus
|
| Interventions: |
DRUG: HRS-1780 tablets|DRUG: HR20033 tablets|DRUG: HRS-7535 tablets
|
| Outcome Measures: |
Primary: PK parameters：Cmax, 0 hour to 24 hours after the last dosing|PK parameters：AUC0-t, 0 hour to 24 hours after the last dosing|PK parameters：AUC0-∞, 0 hour to 24 hours after the last dosing | Secondary: PK parameters：Tmax, 0 hour to 24 hours after the last dosing|PK parameters： t1/2, 0 hour to 24 hours after the last dosing|PK parameters： CL/F, 0 hour to 24 hours after the last dosing|PK parameters： Vz/F, 0 hour to 24 hours after the last dosing|Incidence and severity of adverse events (AEs), from screening to 24 hours after the last dosing
|
| Sponsor/Collaborators: |
Sponsor: Shandong Suncadia Medicine Co., Ltd.
|
| Gender: |
MALE
|
| Age: |
ADULT
|
| Phases: |
PHASE1
|
| Enrollment: |
24
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT
|
| Start Date: |
2024-07
|
| Completion Date: |
2024-07-31
|
| Results First Posted: |
|
| Last Update Posted: |
2024-07-11
|
| Locations: |
Xuanwu Hospital ,Capital Medical University, Beijing, Beijing, 100032, China
|
| URL: |
https://clinicaltrials.gov/show/NCT06495931
|
